Table 1 Patient characteristics
Characteristic | Letrozole alone, n = 25 | Letrozole/bevacizumab, n = 50 | p value |
|---|---|---|---|
Age (years) | |||
 Median (range) | 65 (50.4–86.3) | 61.4 (50.4–81.9) | NSD |
Race, n (%) | |||
 White | 20 (80) | 42 (84) | NSD |
 Black | 3 (12) | 6 (12) | NSD |
 Hispanic | 1 (4) | 2 (4) | NSD |
 Others | 1—Asian (4) | – |  |
Clinical tumor stage, n (%) | |||
 IIA | 9 (36) | 16 (32) | NSD |
 IIB | 7 (28) | 21 (42) | NSD |
 IIIA | 9 (36) | 8 (16) | NSD |
 IIIB | – | 5 (10) | NSD |
Nodal status, n (%) | |||
 N0 | 9 (36) | 21 (42) | NSD |
 N+ | 16 (64) | 29 (58) | NSD |
Tumor type, n (%) | |||
 Invasive ductal carcinoma | 16 (64) | 29 (58) | NSD |
 Invasive lobular carcinoma | 5 (20) | 13* (26) | NSD |
 Invasive mixed carcinoma | 4 (16) | 7 (14) | NSD |
 Others | – | 1—mucinous (2) | NSD |
Histologic grade, n (%) | |||
 Grade I | 6 (24) | 13 (26) | NSD |
 Grade II | 19 (76) | 29 (58) | 0.042 |
 Grade III | – | 8 (16) | 0.025 |